Contemporary challenges in translating biomarker evidence into clinical practice.

p a w c c y s w g s t o i d b c c A i b I w o a q b r a p t p f b e p r u c C p w ith acute heart failure (AHF) being one of the most ommon and costly reasons for hospitalizations in the U.S., stablishing the clinical utility of B-type natriuretic peptide BNP) and aminoterminal pro–B-type natriuretic peptide NT-proBNP) testing has been an important advance in his area. With thousands of papers published, a decade of linical experience, and perhaps the only heart failure iomarker to have its own guidelines endorsement (1), the ar has been set very high for newer biomarkers to demontrate their potential uses in the management of patients ith AHF.